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Role of the disullide bridge and the C-terminal tripeptide in the an-
tidiuretic action of vasopressin in man and the rat. The antidiuretic
action of a number of vasopressin analogues has been measured in
the rat and man in water diuresis. These analogues had the following
categories of structural alteration: a) substitution of —CH 2CH — (di-
carba) and —SCH1-- (6-monocarba) for the natural —SS— bridge be-
tween residues I and 6, b) changes in the nature of the C-terminal
tripeptide produced by substitution of D-arginine and L-N-meth-
ylarginine for L-arginine in sequence position 8 and L-leucme for
proline in position 7, and c) combinations of a and b. In addition, a
highly active analogue which results when valine is substituted for
glutamine in position 4 was tested. Trained, unanesthetized rats and
normal human volunteers were complemented by a volunteer
patient with posttraumatic diabetes insipidus (DI) in the total group
of experimental subjects. The only change in the C-terminal tripep-
tide which was associated with a high antidiuretic action was D-Arg
substitution. The meArg and Leu analogues showed low to very
little activity and no signs of antidiuretic antagonist action. All of
the carba analogues showed both high potency and prolongation of
antidiuretic action in the following order (for both potency and
duration): monocarba + 8-D-Arg > 4-Val + 8-D-Arg > 8-D-Arg
alone, all in deamino form. None of the 8-D-Arg analogues had
any side effects on the cardiovascular system, gut, uterus, bladder,
etc. The prolongation was such that even with a DI patient refrac-
tory to the action of lysine-vasopressin and relatively resistant to
deamino-[8-D-Arg]-vasopressin, water turnover could be reduced
from untreated levels of 20 to 30 liters/day to <2 liters/day with
only a single administration of deamino-6-carba-[8-D-Arg]-vaso-
pressin as nose drops. The significance of these structural altera-
tions in the vasopressin molecule for interaction with both anti-
diuretic and smooth muscle receptors was discussed.
Le role du pont disulfure et du tripeptide C terminal dans l'action
antidiurétique de Ia vasopressine chez l'homme et le rat. L'action an-
tidiurétique de divers analogues de Ia vasopressine a été mesurée
chez Ic rat et l'homme en situation de diur'ese aqueuse. Ces ana-
logues ont les modifications structurales suivantes: a) substitution de
ponts —CH2CH2- (dicarbone) et —SCH2-- (monocarbone) au Pont
disulfure naturel entre les résidus 1 et 6, b) alterations de Ia nature
du tripeptide C terminal obtenues par substitution de D-arginine et
de L-N"-methylarginine a Ia L-arginine en position 8 dans Ia
sequence et de Ia L-leucine a Ia proline en position 7, c) combinaison
de a et b. Dc plus, un analogue très actif, obtenu par substitution de
Ia valine a Ia glutamine en position 4, a été essayC. Des rats en
trainCs, non anesthésiés, des humains volontaires et un malade, vol-
ontaire, atteint de diabète insipide ont constitué Ic groupe
experimental. La seule modification du tripeptide C terminal qui
perinet une action antidiurétique importante est Ia substitution de
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D-arginine a Ia L-arginine. Les analogues methyl arginine et leucine
ont une très faible activité et n'ont pas d'effet antagoniste. Tous les
analogues oü le pont disulfure est remplacé par une structure dicar-
bone ou monocarbone ont une action antidiurétique puissante et ef-
ficace dans l'ordre décroissant (a Ia fois pour l'intensité et Ia durée)
suivant: monocarbone + 8-D-Arg > 4-Val + 8-D Arg> 8-D-Arg
seul, tous sous a forme désanimée. Les analogues 8-D-Arg n'ont
pas d'effets secondaires sur Ic système cardiovasculaire, l'intestin,
l'utCrus, Ia vessie etc. La prolongation de l'effet est telle que chez un
malade atteint de diabète insipide rCfractaire a Ia lysine vasopres-
sine et relativement resistant a Ia 8-D-Arg-Vasopressine, Ic renou-
vellement de I'eau a pu être réduit de 20 a 30 litres par jour avant
traitement a moms de 2 litres par jour par une seule administration
de desamino-b-monocarbone-(8-D-Arg]-vasopressine sous forme
de gouttes nasales. La signification de ces modifications structurales
de Ia molecule de vasopressine en cc qui concerne !'interaction
avec les récepteurs antidiurCtiques et musculaires lisses est discutée.
Vasopressin (VP):
A B C
1 2 3 4 5 6 7 8 9 (AVP)
Ly (LVP)
D
has probably the lowest hormonal threshold known
for its interaction with the antidiuretic (AD) recep-
tor—10'3 moles/kg for exogenous doses during water
diuresis [1]. This represents one to two orders of ten
fewer molecules than the threshold for any measurable
response of vascular, gut or uterine smooth muscle
(SM)— the next most sensitive systems in the wide bi-
ological spectrum of VP activities [2]. Dividing this
value by the number of nephrons in man or the rat
yields a range of about 5 x 1O to 5 x 1O molecules
available per nephron under the above conditions.
Since some of the injected moecules will be picked up
elsewhere ("loss receptors") and a large portion will
be enzymatically inactivated before the molecule
comes into contact with AD receptors [3], the number
of interacting molecules in the kidney will be far less.
This striking difference between thresholds of AD and
SM receptors can only reflect a correspondingly high-
er affinity of the AD receptor for VP [4], particularly
in view of the relatively small tissue mass involved in
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urine concentration in relation to the total mass of tis-
sue capable of reacting with this peptide.
At low doses, biological activities of VP have a
short half-life of 10 to 30 mm, and the metabolic half-
life of injected hormone in the blood is only 3 to 4 mm
[5]. Only a small portion of an injected dose is ex-
creted as intact nonapeptide and the main reason for
the short action of the hormone is enzymatic cleavage
[3, 5]. There are four demonstrated sites of initial
proteolytic cleavage (refer to the sequence diagram
above): aminopeptidase splitting A) between 1 and 2
in most tissues, B) between 6 and 7 in a small region of
the diencephalon, C) between 8 and 9 (demonstrated
in the kidney but possibly elsewhere as well) and D)
between the two sulfurs of the 1-6 bridge (demon-
strated in the liver, but it may exist elsewhere) [4, 6—
10]. Because the blood flow rates to kidney, liver and
muscle are so high, one would expect cleavage sites A,
C and D to be quantitatively the most important [4, 6,
9] but it should be stressed at the outset that because
appropriately labelled peptides have not been avail-
able, no quantitative comparisons of these cleavage
rates can yet be set down, nor do we know if the above
list of initial cle4vage sites is complete. On the as-
sumption that removal of the Naamino group would
slow A cleavage and substitution of D-Arg for the L-
isomer at position 8 should prevent C cleavage, the VP
analogue deamino-[8-D-Arg]-vasopressin (dDAVP)
was synthesized and proved to have a much higher AD
activity than AVP, lasting for seven to ten hours after
a single administration, with only Y1000th the pressor
activity of the parent hormone [I 1—13]. Because of
these features, and its commercial availability, several
clinical studies have considered dDAVP the treatment
of choice for central diabetes insipidus (DI) particular-
ly since there are no side-effects even with large doses
[11, 14, 15]. This striking change in the VP biological
spectrum—due primarily to the steric change in the
8th residue—still lacks an adequate theoretical ex-
planation.
In the present study the following categories of VP
structural change are dealt with: a) alterations in the
C-terminal tripeptide which presumably affect the
conformation of this part of the molecule but leave the
omega amino group at 8 intact (N'-methylarginine at
8 and substitution of leucine for proline at position 7),
b) alterations of the disulfide bridge (6-monocarba—-
an SCH2 bridge—and l,6-dicarba—-a CH2CH2
bridge) which should render this site in the molecule
more metabolically stable to D-cleavage, c) a highly
active analogue of dDAVP, with valine instead of
glutamine in position 4 [16] and d) combinations of
the above, and with D-Arg in sequence position 8. Ac-
tivities were measured in unanesthetized rats and hu-
man volunteers, b9th in water diuresis, and in one
patient volunteer with posttraumatic DI. dDAVP was
selected as the reference peptide in this series, rather
than AVP, because the former has a more or less pure
antidiuretic action, while the latter may cause some
hemodynamic change at higher doses which could al-
ter the AD response.
Methods
Materials. AVP and dDAVP (Minirin) [131 were
the commerical products of Ferring, Ltd., Malmö. Dea-
mino-[8-N-methylarginine]-vasopressin (dNmeAVP)
was supplied by Prof. F. Sorm of this Academy Insti-
tute. [7-Leucine]-arginine-vasopressin and [7-leucine,
8-D-arginine]-vasopressin (LAVP and LDAVP) were
prepared by Dr. Lars Carlsson at Ferring, and the
former alone was also prepared by Dr. D. Gillessen of
Roche, Ltd., Basel. One of us (KJ) synthesized deam-
ino-6-carba-arginine-vasopressin (dCAVP) and deam-
ino-6-carba-[8-D-arginine]-vasopressin (dCDAVP)
[17]; and Prof. R. Walter of the Mount Sinai Medical
School, New York City, supplied deamino-l,6-di-
carba-arginine-vasopressin (dCCAVP) [18]. Deam-
ino-[4-valine, 8-D-arginine]-vasopressin (dVDAVP)
[16] was supplied separately in two batches of identi-
cal activity by Prof. W.H. Sawyer of the College of
Physicians and Surgeons, New York City and by Fer-
ring. The structural formulae of these compounds
have been presented elsewhere [4] and for illustrative
purposes only the nature of the separate changes in the
VP molecule involved are summarized in Table I.
All peptides were available as freeze-dried powders,
peptide content >99% by weight. They were all chro-
matographed here to be certain that only monomer
was present in a single, clean peak. Stock solutions
were made up from weighed amounts once or twice
Table 1. Review of basic chemical alterations in the vasopressin
molecule,and symbols used in the text
Sequence
position AVP Analogues Symbol
1-Cys
4-GIn
NH2—C
Gin
H—C
Val
d (deamino)
V
6-Cys
1,6-Cys
R
I(S)SR R
I ISS
R
I(S)CH2R R
I I
H2C_CH2
C (carba)
CC (dicarba)
7-Pro Pro Leu L
8-Arg L-Arg D-Arg DA
8-Arg R
I
-N(H)-CH-C(O)-
R
NmeA
-N(CH3) -C H -C(O)-
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weekly, at a concentration of 0.1 mg/mI of sterile
physiological saline, pH 3.5 (added HCI) and kept at
3°C. The dry powders were kept at —40°C in sealed
tubes. Stock solutions were diluted for testing with sa-
line under sterile conditions and used within 20 mm;
the unused, diluted remainder was discarded. Sterile
stock solutions werefldministered as nose-drops to hu-
man volunteers directly, using 0.5-mi calibrated sy-
ringes (Inaltera).
The rat assay. A modified Burn assay was carried
out on unanesthetized Wistar strain male rats [12, 19].
Groups of 36 to 54 animals were started on training
when they reached a body wt of 130 to 150 g. Every
other morning on weekdays a polyethylene stomach
tube was inserted and a small hypodermic needle was
introduced s.c. in the inguinal region. The animals
were then placed for 2-hr adaptation into separate,
small plexiglass metabolic cages with a stainless steel
grid floor (wires, 1 cm apart) connected to a plexiglass
funnel designed at the tip to separate feces from urine,
and surface-treated with Bryj 35 for quantitative col-
lection of small volumes of spontaneously voided
urine. There were 18 such cages. By the second or
third training period the animals accepted intubation
without protest and spent most of their time in the
cages either asleep or with exploratory behavior, most,
however, emptied their bladders during intubation.
Experiments were started when the animals reached a
body wt of 190 g and continued up to a body wt of 250
g, with a maximum of four test periods per rat. Before
being tested, the animals were fasted overnight to en-
sure an empty stomach, but had ad lib water available
in stock cages of six animals each. In the morning they
were weighed to an accuracy of 1 g and then re-
ceived a 2% (vol/wt) load of tap water at about 30°C
as the standard oral hydration. Peptides were adminis-
tered s.c. in a constant volume dose of 0.1 mI/100 g of
the required dose in saline. Controls received the same
volume of saline alone. The time of loading was re-
corded separately for each animal and urine volumes
were recorded at 10- to 15-mm intervals for a maxi-
mum of 300 mm. In subsequent experiments the ani-
mals were rotated so that each rat in a group of 18
served as a control once and received various doses of
a peptide for three further assays. The reasons for the
training, the time and body wt limits and total number
of assays limit will be given in Results. In order to de-
fine assay conditions more clearly, a separate group of
36 trained rats was left without an orally administered
water load for 300 mm as a further control. A maxi-
mum of two experiments per week was carried out
with each group of 18 animals, with two days' rest in-
between.
The number of minutes required for excretion of
50% of the orally administered load was recorded
from the time of loading for each animal separately. If
the 50% mark was reached between two collection pe-
riods, a linear extrapolation was made to calculate the
tY2—or time of half-excretion. Means and SEM'swere
calculated from each assay. Since log dose vs. re-
sponse curves for dDAVP are not linear [11, 12] and
since we were comparing the actions of pure, synthetic
substances, the classical LU/mg expression of AD ac-
tivity—referred to international standard pituitary
powder—was not used. Instead, a convenient delay
time in the response curve to dDAVP was selected in a
linear portion of the curve of log dose vs. response
(200 mm, controls with an average tV2 of 41.6 1.4
mm) and the activities of other analogues were ex-
pressed relative to standard dDAVP, comparing 200-
mm points on the curves. This approach avoided the
error which can accrue from extrapolating threshold
doses in a nonlinear portion of the curve (see Fig. 2).
Analogues with a low AD activity were tested for
possible antidiuretic antagonist properties by com-
bining them in the same s.c. administered injectate
with reference dDAVP and AVP in analog:reference
molar ratios which ranged from 1.0 to 500. In these as-
says there were two control groups: the same dose of
reference peptide alone and the same dose of possible
antagonist alone. A further experiment to test possible
antagonism was carried out with fresh plasma from
the DI patient (see following) because of her refrac-
tory state to the actions of both LVP and dDAVP.
Blood was sampled during a control day without treat-
ment, fresh plasma was separated and dDAVP was
added to a final concentration of 10 ng/ml. The mix-
ture was left standing at room temp for 20 mm and
was then diluted with saline for rat assay. As a control,
plasma alone was diluted to the same degree. Trained
rats then received 50 and 100 pg/ 100 g of body wt
doses of a)dDAVP diluted in saline alone,b) dDAVP
after being mixed with plasma and c) the same quanti-
ty of diluted plasma alone.
Clinical pharmacology. 1) Healthy volunteers. Each
of the five subjects was tested once weekly. The only
intake at breakfast was 250 ml of unsweetened tea. At
7:30 AM the bladder was emptied and the subject drank
within 20 mm 0.5% (vol/wt) of his body wt as unsweet-
ened tea made up in tap water—temperature, 20 to
30°C. The first urine samples were collected by spon-
taneous voiding at 8:30 AM and the subject then drank
the same volume of tea as urine voided + 1 ml for
each mm of the clearance period to cover insensible
losses. All further collection periods were 30 mm in
duration, with the same maintenance load drunk as
above. A balanced state of water diuresis was attained
by 9:30 AM and peptide was administered at the start
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of the fourth collection period as nose-drops given
slowly into both nostrils, in a supine position with the
head well back. Blood samples were taken from the
antecubital vein at 10:30 AM, by which time peak anti-
diuresis had been reached. The last urine sample was
at 11:00 or 11:30 AII, following which the subject had
lunch but continued to record voided urine volumes
and times until urine flow rate reached 50% of that at
maximal diuresis, before the peptide was given, as an
estimate of response duration. Blood pressure and
pulse rates were measured at 30-mm intervals for the
first three hours.
2) The DI patient. A 33-yr-old woman physician
who, 18 months previously while in the third month of
pregnancy, had been involved in an automobile acci-
dent with a head injury which resulted in DI, also vol-
unteered. Untreated water turnover was 20 to 30 lit-
ers/day. Soon after the accident, attempts to use LVP
to treat the DI had to be abandoned because of uterine
contractions, and she was put on a regimen of
dDAVP—50 tg/day intranasally—which carried her
without further event through pregnancy and normal
delivery of a normal newborn. She has been on a regi-
men of dDAVP ever since, but is the only one of over
200 DI patients on this drug (for up to nine years) to
have become relatively unreactive to the analogue
(and extremely resistant to LVP). At the time of this
study, her requirment for a daily water turnover of <2
liters was 50 zg every six hours, or 200 Mg/day, with
no side-effects. For the duration of the present study,
as she was put on a constant daily diet and the follow-
ing regime:
6:00 AM—light constant breakfast; 6:00 to 9:00 AM—
urine collection; 9:00 AM to 12:00 noon—three one-
hour clearance periods, blood sampled at 12:00 noon,
then constant lunch; 12:00 noon to 6:00 PM—two
three-hour clearance periods; 6:00 PM—constant sup-
per, followed by administration of 40 tg of dDAVP
intranasally to prevent excessive urine volumes from
interfering with sleep; 6:00 PM to 6:00 AM—measure-
ment of urine volumes and voiding times.
The 6:00 to 9:00 AM urine portion represented mini-
mum water reabsorption, the 10:00 AM to 12 noon pe-
riods were those of the maximum response to the pep-
tide. The subsequent periods were a rough measure of
response duration (with the constant error throughout
of the evening dDAVP, which was a condition set by
the patient). There were four experimental days in the
middle of a menstrual cycle: 1) no peptide as a control,
2-4)40 ig doses of dDAVP, dVDAVP and dCDAVP
in that order. Double-blind conditions were main-
tained throughout all the clinical pharmacology, the
detailed nature of the experiment was explained to all
of the non-authors who served as subjects (see Ac-
knowledgements) and informed consent was obtained.
All electrolyte measurements were carried out by
routine flame photometry, urine osmolarity was meas-
ured with a Knauer osmometer and creatinine concen-
trations were measured as described elsewhere [20].
All calculations of derived values from measured
clearance data obtained under the above conditions
have been presented elsewhere [21]. Statistical treat-
ment of the data was by paried co-variance analysis.
Results
The rat AD assay. Figure 1 shows cumulative urine
excretion vs. time in trained rats in the given weight
range over 300 mm, starting from 7:30 AM a) when no
orally administered water load is given (bottom curve,
N = 36) b), with an orally administered load of 2% of
body wt (top curve, N = 60) and c) the arithmetic dif-
ference between the two curves. The ordinate is a per-
centage of the water load given, so that for the un-
loaded controls 100% = 2% of body wt in milliliters.
Both top and bottom curves have very small SEM val-
ues, provided the rats are trained to the experimental
conditions described. Without training, the mean
points are the same but the SEM values are ten times
B
C.)
100
A
C
B
0 100 200 300 mm
Fig. 1. Cumulative urine excretion in trained rats after a 2% of body
wi oral load (top curve A), with no oral load (bottom curve B) and
the arithmetic difference (curve C). Ordinate, % of oral load = 2%
of body wt. Abscissa, time in mm. For curves A and B, mean values
SEM.
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greater in the same body wt range. The top curve is
shited to the left in younger rats, body wt <160 g, and
shifted to the right in rats of body wt > 260 g (for the
wt range 260 to 300 g, mean tY2 was 53 mm as com-
pared with data below). In the weight range used, the
results formed an homogenous population. When a
given group of rats was tested more than four to five
times, particularly with different VP analogues, there
was often a sudden shift of the dose-response curve to
the right and a loss of sensitivity to all AD peptides.
Under the stated conditions, t½ with a 2% of body wt
water load was 41.6 1.4 mm. If an excretion t½ is
read off from the difference curve in Fig. 1, the cor-
rected value (minus spontaneous loss without a load)
would be 75.2 mm for the half-excretion of the load it-
self. In the present data, for the sake of simplicity,
only the top curve, or a subtraction of 41.6 mm, was
used to correct the delay times after peptide adminis-
tration.
Figure 2 shows log dose vs. response (t
experimental
to t½ control) curves for most of the VP analogues
tested. Only means are given because the curves are
so close together that SEM lines would only be con-
fusing; statistical analysis of the 200-mm comparison
point for all analogues is given in Table 2. As pre-
viously reported for dDAVP, this dose-response rela-
tion is not linear when D-Arg replaces the L-isomer
in the C-terminal tripeptide [11, 12]. The curves were
most nearly parallel at delay time 200 mm, which was
taken as the point of comparison (see Methods).
Doses of different analogues which produced this same
(/7
1O 102 i03 o4
Analogue Ratio n
dDAVP 1.00±0.12 20
AVP 0.52 0.08 20
dCDAVP 3.75 0.56 20
dCAVP 2.93 15
dCCAVP 2.74 0.35 15
dVDAVP 1.47 0.13 20
dNmeAVP 0.16 20
LAVP 0.02 0.01 5
LDAVP 0.02 0.01 5
200-mm delay were compared with doses of the most
appropriate parent substance of the series, dDAVP,
the response to the latter being arbitrarily set at 1.00.
The order of activities was dCDAVP > dCAVP >
dCCAVP > dVDAVP> dDAVP> AVP> dNme
AVP >> LAVP = LDAVP. The equi-active doses
of analogues which resulted in a 200-mm delay in t½
were expressed as potency ratios to dDAVP (Table
2)—i.e., a ratio of 5.0 means that one-fifth the dose of
analogue X was equi-active to dDAVP, a ratio of 0.5
means that twice the dose of analogue Y was equi-
active to dDAVP.
dNmeAVP, LAVP and LDAVP were tested for
possible antagonist properties to the AD activity of
dDAVP and AVP. No differences were found in the
LAVP and LDAVP assays between the groups with
reference peptide alone and the groups with the same
dose of reference peptide plus up to 500 times the
amount of 7-Leu analogue. In the case of dNmeAVP,
the group with combined doses (molar ratios up to
100) showed only an additive AD effect of the two pep-
tides. There was no evidence of antagonism at the AD
receptor.
Healthy human subjects. The five subjects received
various doses intranasally of only three of the more
active analogues with no side-effects: dDAVP,
dVDAVP and dCDAVP, in addition to only saline
nose-drops as a control run. Table 3 shows that none
of the administered analogues had any measurable
cardiac or pressor effect in doses which reached 85 g
in one case. There was also no change in the excretion
of Na or K, or any constant or significant change in
total osmolar exretion. There was a decrease in gb-
merular filtration rate, GFR (creatinine clearance,
Car), in all subjects at the height of the water diur-
esis—since this was present to the same degree in all
subjects in the control run as well it can be attributed
to the water loading, not to a vascular effect of the an-
Table 2. Potency ratios (see Methods and Results) of the AD
action of VP analogues, referred to dDAVP activity =
Ratios are means SaM, n = degrees of freedom.
0 All carba vs. AVP, dDAVP, dNmeAVP, LAVP, LDAVP: P <
0.001; all carba vs. dVDAVP; P < 0.01; dCDAVP vs. dCAVP:
P = NS; dCrAVP vs. dCCAVP: P <0.05.
III!! /
300
260
220
180
140
100
60
20
pg/]OO g
Fig. 2. Rat assay comparison of AD activities of VP analogues, log
dose (pg/IOO g of body WI) vs. response (mean t½ after a 2% of body
WI oral load). Ordinate: (t½.0 tV200,,t) or (t½meaurod 41.6).
R = reference peptide dDAVP, 1 = dCDAVP, 2 = dCCAVP, 3 =
dVDAVP, 4 = dNmeAVP, 5 = combined results for LAVP and
LDAVP. The curve for dCAVP lay between 1 and 2, and was
omitted to prevent crowding. SEM lines at each mean point also
were omitted to prevent crowding. For statistical comparison at
200-mm delay time, see Table 2.
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alogues. Since with oliguria the percentage of error in
volume of spontaneously voided urine increases, (UI
V> p) and (U/P)osm were taken as the most appropri-
ate measures of peak AD potency. Comparisons of 5
C) g doses in all subjects revealed the same order of
°, activities as that observed in the rats: dCDAVP >
LY dVDAVP > dDAVP. The dose-response curves,
despite the small numbers, also showed the same order
of shift to the left (with respect to dDAVP) for the
analogues (Fig. 3, response = MA/D ratio of
(U/P)cr where MA is maximal antidiuresis and D is
prepeptide diuresis; Fig. 4, response = MA/D ratio
of (U/P)osm). Table 3 and Fig. 5 also show the same
order of persistences of the AD responses to the
three analogues. In Fig. 5, response is only urine flow
rate in ml kg-' min', since complete urine analyses
were available only for samples collected for 2.5 to 3
hr after peptide administration, after which volumes
alone were recorded. It should be stressed that a con-
stant 0.5% water excess was maintained only for three
hours after the peptide, as indicated by the vertical
dashed line, after which water intake was ad lib and
8 the fast was broken. Despite these limitations it is still
striking that if we take as reference the highest re-
sponse (to 5 tg of dCDAVP), both an equimolar (5
tog) and an equi-potent (peak response) (20 ig) dose
of dDAVP showed a much steeper slope of the diur-
esis-retum portion of the curve, indicating the pro-
longed nature of the AD response to the carba ana-
logue. The slope of the same portion of the dVDAVP
curve was between the above two extremes.
The DI patient. Table 4 compares the responses of
the DI patient to 40 tg intranasal doses of dDAVP,
dYDAYP and dCDAVP on successive days under
comparable conditions. Here again, both in terms of
. peak responses and particularly response durations
the order of effectiveness was dCDAVP > dVDAVP
> dDAVP. Response duration in this case was dis-
torted by the fact that in addition to the morning
experimental peptide dose, there was a constant 40
tg dDAVP evening dose (which the patient insisted
upon) to make sure that she had sufficient sleep. This
artefact did not effect the peak antidiuretic responses
near noon, and was in any case a constant one on all
four days, so that the results can be compared. In
this refractory patient only the carba analogue was
able to induce a physiologic level of antidiuresis
which lasted more than 24 hr after a single intranasal
administration.
Table 5 shows that the patient's plasma, sampled on
the control untreated day, showed no AD activity in
the rat assay, nor did the presence of this plasma affect
. the AD activity of dDAVP in the same assay. There
was no evidence of an anti-dDAVPactivity of any sort
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Fig. 3. Dose-response relations in five healthy subjects in the AD
activity of three VP analogues. Ordinate: (U/P)cr,MA/(U/P)cr,D,
where MA = maximal antidiuresis and D = diuresis before peptide
administration. Abscissa: log total intranasal dose in g. For all
other symbols, see Table 3.
in the plasma which might be related to the patient's
refractory state.
Discussion
Every biological assay has a time interval in which
the state of the system is sufficiently stable to allow
drug-induced transients to be reliably measured.
When each transient time is a small fraction of total
usable time of the system (e.g., pressor assays), the ki-
netics of the transients can be analyzed to give infor-
mation on peak potency, "receptor affinity", response
persistence, compartment distributions, etc., and sepa-
rate doses of different substances can be repeated in
the same system for greater reliability. AD assays in
all their many variants—rats unanesthetized or
anesthetized with alcohol or barbiturates—share the
common difficulty of constancy of the water excess to
be excreted and stability of renal function. When
short-acting hormones such as AVP are compared
— SdVDAVP
SdDAVP
'20 dDAVP
1 0 2 4 6 8 10 12 14 16 18 20 22
hr
Fig. 5. Duration of AD effect of three VP analogues in five healthy
subjects. Ordinate: ml of urine kg' min', abscissa time in hours
after peptide administration (0 time). For 5 g doses of dDAVP,
dVDAVP and dCDAVP, mean values SCM. For 20 g dose of
dDAVP, only mean values (n = 3). For purposes of comparison,
the 5 zg doses were equi-molar, the 20 g dose of dDAVP was
equi-peak-potent to 5 ig of dCDAVP. Note the slope differences in
the diuresis-return portion of the curves. Time — Ito 0 hr. baseline
diuresis; time 0 to 3 hr, time of maintained water excess. After
time 3 hr. water was given ad lib.
with equally short-acting analogues, the total usable
time of the system is not a problem. When the dura-
tion of action of an AD peptide approaches, or even
exceeds, total usable time of the system 1)the degree
of scatter in any index used for comparison can be ex-
pected to increase, 2) analysis of the kinetics of single
response transients loses much of its quantitative val-
ue and 3) wide variations in mean activity values can
result [see 17, 18]. An example of these difficulties is
the wide variation in reported "absolute" (lU/mg) ac-
tivities of dDAVP itself [11—13, 16, 25] and for these
reasons activities in the present report have all been
expressed as relative to a pure, synthetic standard—
dDAVP—which is commercially available. The modi-
fied Burn assay presented here was developed as the
simplest and most reliable we have yet experienced,
which requires no more than adequate metabolic
cages to be set rapidly into operation and enables rap-
id accumulation of data. The modifications were sev-
eral in number. The orally administered load—2% of
body wt—was smaller than that used by others (4 and
8% [12, 19, 22]) but this can be considered a physi-
ologic advantage since the results were reproducible
without a long period of extracellular fluid hypoos-
molarity (in the case of long-acting peptides). Total
assay duration was limited to 300 mm, which was con-
sidered necessary because longer periods without food
after an overnight fast (common to all assays) might
well result in other metabolic artefacts. Doses of pep-
tides had to be selected to fit into a tY2 range of 50 to
300 mm. The usable age range (as a function of body
wt) was defined, since sensitivity decreases with age.
Finally, the total number of assays per animal was
limited, since it would appear that sensitivity can be
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Fig. 4. Dose-response relations in five healthy subjects in the AD
activity of three VP analogues. Ordinate: (U/P)om,MA/(U/P)o,m,D.
For other symbols, see Fig. 3.
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Table 4. AD responses of Dl patient to three VP analogues administered in doses of 40 ig intranasally on three consecutive days (following a
control day with saline nose-drops only) (see Methods and Results)a
Total
Analogue P BP Ccr tY2 (U/P)cr D: MA Co,m/Ccr CNa/Ccr CK/Ccr urine/day
Control
D
—2 0 + II — 20.9 1.69 1.35 0.24 6.8 7560
MA 12.4 1.93 0.80 15.3
d DAV P
D + 8 + 15 — 17 7.0 10.5 0.165 2.85 0.66 14.5 6690
MA 63.8 2.43 0.74 19.3
dVDAVP
D
—6 + IS — 16 15.3 13.8 0.121 1.59 0.29 5.9 5725
MA 113.8 1.72 0.40 11.9
dCDAVP
D + 12 + 7 — 18 32.5 10.8 0.081 2.12 0.51 8.4 2022
MA 132.4 1.65 0.48 14.8
For all symbols, see Table 3.
All data under the influence of a constant artefact—an evening intranasal dose of4O tg ofdDAVP to ensure adequate sleep (which explains
the low "control day" urine volume, see Methods).
Table 5. Effect of "incubation" of dDAVP in the serum of a Dl patient resistant to both dDAVP and LVP on AD activity in trained rats
(cf. Methods)
Injectate t'/z (means min SEM) n
Controls (only 2% water load) 41.6 1.4 t½, measured 60
Injected controls (diluted plasma) 43.6 2.3 t½, measured 10
50 pg/l00 g of dDAVP in saline alone 65.4 + 2.1 t½, corrected 20
100 pg/l00 g of dDAVP in saline alone 210.5 + 3.8 t½, corrected 20
50 pg/100 g of dDAVP in saline-diluted plasma 62.6 2.5 t½, corrected 10
100 pg/lOO g dDAVP in saline-diluted plasma 212.4 5.8 t½, corrected 10
lost after too many exposures to different but related
peptides, for reasons as yet unexplained. It is tempting
to relate this last point to the clinical observation that
DI patients can become refractory to LVP (not the
human hormone) administration by any route in time,
and even to dDAVP as shown by the DI patient in
this report. No evidence was found that this refrac-
tory state, either in patients or rats, is related to an
anti-VP activity (antibody or enzymatic) in plasma,
so that the explanation might lie at a tissue (receptor)
level. A further possibility awaits testing—that
peptide administration can "activate peptide inactiva-
tion" by enzymes cleaving at sites to be determined.
As shown in Fig. 1, after a 2% orally administered
water load any t½ > 50 mm can be considered evi-
dence of AD activity of an injected peptide, provided
that all other conditions of the assay are held to.
The nature of the chemical alterations in the VP
molecule dealt with here—hydrophobic substitutions
and changes which theoretically should interfere with
three of the four known sites of initial enzymatic
cleavage, and conformational sequelae therefrom—
raises the possibility that every stage of the kinetics of
peptide action (compartment distribution, metabolic
stability to cleavage, affinity and rate of receptor corn-
plexing, intensity of response triggering, peptide-re-
ceptor complex duration and inactivation, etc.) has
been affected. The ideal assay animal is man, because
his usable assay time is long and we can compare equi-
peak-potency (as a function of (U/P)r, (U/P)osm or
CH20) dosages and follow subsequent kinetics with a
cooperative subject. All lower animal assays are com-
promises which give rough comparisons of a summa-
tion of all of the above factors. Large changes of either
sign can at most suggest that one or another index has
been altered, but little more. More detailed analysis of
these kinetic stages will require the use of the same
peptides labelled at several different sites, used in dif-
ferent types of system. This applies to the conclusions
of Sawyer, Acosta and Manning [25] that the deamino
change is critical for prolongation of the response in
non-carba VP analogues, while the 8-D-Arg change
only suppresses SM activity. Since a) cleavage at any
site in the VP molecule results in a drastic loss of all
activities, b) C-cleavage has been demonstrated using
'4C-Gly labelling and c) no known trypsin-like (cleav-
ing next to basic residues) enzyme activity cleaves at
D-isomers, it is difficult to accept that D-Arg does not
increase the biochemical stability of the molecule only
on the basis of AD assays on intact rats. The high and
prolonged AD activity of dVDAVP [16, 25] has been
confirmed, even quantitatively, and shown to apply to
the human. The very nature of the V change (see Table
1)—hydrophobic substitution at the "least crowded"
site in the molecule—suggests (but does not prove)
that receptor-analogue affinity has been increased.
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Aside from position 4, structural aspects of the VP
molecule which influence AD activity can be discussed
under two headings: a) the C-terminal tripeptide (posi-
tions 7-9) and b) the disulfide bridge. The importance
of the basic residue in position 8 for both AD and SM
activities has long been recognized [2, 4, 16, 17, 23,
24]. It can be assumed that the omega amino group at
8 interacts noncovalently with the receptor [see 4]. The
striking feature—with clinical implications—of the
present and other [Ii, 121 data is that one steric
change at this site (D- instead of L-Arg) practically
eliminates SM activity, whereas two other structural
(and presumably steric) changes in the C-terminal
tripeptide either decreased or practically eliminated
both AD and SM activities despite the continued pres-
ence of the omega amino group at 8 (8-meArg and 7-
Leu). Since dNmeAVP, LAVP and LDAVP also
showed no signs of antidiuretic-antagonistic proper-
ties, it is possible that the structural changes have in-
terfered with AD receptor binding. As a ring-contain-
ing residue, proline tends to limit rotation about
neighboring peptide bonds [26] which should limit the
number of possible configurations of the C-terminal
tripeptide. Substitution of Leu at 7 offers greater rota-
tional freedom in Dreiding models. Were 7-Leu to in-
terfere with B-cleavage, if anything AD activity would
be higher. Since the activities were very low, it can
only be suggested that the hydrophobic influence of
Leu at 7 interferes with noncovalent interaction of the
adjacent omega amino group. Introduction of an N-
methyl group directly on the peptide chain between 7
and 8 (dNmeAVP) also involved hydrophobicity, but
not adjacent to the omega NH2. In the latter case it
can be suggested that the steric result sufficiently
changed the orientation of the omega NH2 to prevent
receptor interaction at this site. One explanation for
the dissociation of the biological activity spectrum of
VP caused by 8-D-Arg substitution has already been
presented [4] and is summarized in Fig. 6. Rotation
about the 7-8 C-N bond permits the same omega NH2
interaction as with the L-isomer, but leaves 9-Gly-
amide projecting at an angle of 1200 from its usual
orientation towards the ring. If this explanation
proves to have substance, AD receptors would differ
from SM by having sufficient conformational room
for this latter effect not to interfere with peptide in-
teraction; it would also suggest a different role for
Gly-amide in the two receptor categories.
Provided that the 1-6 ring size is not altered, all
known oxytocin and VP mono-carba analogues are
characterized by both high potencies and long dura-
tions on SM systems [27—30] and, in the present case,
on AD as well, in comparison to parent hormone
molecules. This alteration also appears to do very
Fig. 6. Summary of some structural aspects of ihe VP molecule which
may influence AD receptor interaction (see /4/). X = disulfide
bond, not involved in the receptor interaction, but a limiting factor
determining the duration of the interaction; A noncovalent inter-
action of the p-OH group of the Tyr aromatic ring [23]; B
proposed region of possible hydrophobic interaction [16]; C =
omega amino group interaction, noncovalent (see[4]).---(Gly) =
proposed result of Orientation of 9-Gly when 8-D-Arg is sub-
stituted for the L-isomer (see Discussion).
little to the conformation of the ring backbone [31,
32]. Dicarba analogues have a prolonged action on
SM, but with decreased potency [18, 27—30}. The AD
activity of dCCAVP is both high and prolonged (see
Results and [18])—further evidence for the view that
SM receptors have much higher conformational re-
quirements than AD. It has been suggested elsewhere
[4] that the disulfide bridge, not involved in the pep-
tide-receptor interaction (see Fig. 6), is an important
metabolic limiting factor determining the duration of
this interaction. Since —SCH2-- and —CH2CH2—
bridges in the present analogues would be more meta-
bolically stable than —SS—, a) increased potency and
response duration could result and b) disulfide bond
splitting could be an important intrarenal mechanism
of terminating VP action in the kidney. There is one
further theoretical possibility—that the mono-carba
modification improves conformational "fit" of the
peptide to its receptor. There is no technique at
present available to test this possibility.
The clinical implications are clear. If pure antidi-
uresis, without cardiovascular or other smooth muscle
or metabolic complications, is required for any pur-
pose (DI in adults or children [33], X-ray visualization
of the kidney [34, 35], nocturnal enuresis, "social"
uses or determination of the concentrating ability of
the kidney without resorting to dehydration [36]), any
of the three reported VP analogues with D-Arg at posi-
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tion 8 is to be preferred to the natural hormones, or
nonhormonal drugs [11, 14, 15, 33, 36]. "Potency" for
the patient is a combination of response amplitude
and duration, the latter being more important. Of the
three reported analogues, one can select between ex-
tremes of 6 to 10 hr (dDAVP) and > 24 hr
(dCDAVP) or something inbetween (dVDAVP) with
a single intransal dose. It is a question of clinical
judgement as to how long a response should be, since
the subject cannot excrete a water load while under
the influence of these peptides. dDAVP would ap-
pear to suffice as treatment for practically all cases
of central DI.
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